168 related articles for article (PubMed ID: 37301715)
21. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
22. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Plaçais L; Dalle S; Dereure O; Trabelsi S; Dalac S; Legoupil D; Montaudié H; Arnault JP; De Quatrebarbes J; Saiag P; Brunet-Possenti F; Lesimple T; Maubec E; Aubin F; Granel-Brocard F; Grob JJ; Stoebner PE; Allayous C; Oriano B; Dutriaux C; Mortier L; Lebbe C
Ann Rheum Dis; 2022 Oct; 81(10):1445-1452. PubMed ID: 35788496
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N; Uhara H; Fukushima S; Uchi H; Shibagaki N; Kiyohara Y; Tsutsumida A; Namikawa K; Okuyama R; Otsuka Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):969-75. PubMed ID: 26407818
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C; Hoefsmit EP; Fangmeier T; Kramer N; Kabakci C; Vera González J; Versluis JM; Compter A; Harrer T; Mijočević H; Schubert S; Hundsberger T; Menzies AM; Scolyer RA; Long GV; French LE; Blank CU; Heinzerling LM
Cancer Immunol Immunother; 2023 Nov; 72(11):3475-3489. PubMed ID: 37606856
[TBL] [Abstract][Full Text] [Related]
25. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
27. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
28. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
29. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
30. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
31. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
[TBL] [Abstract][Full Text] [Related]
32. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
[TBL] [Abstract][Full Text] [Related]
33. Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis.
Dimitriou F; Staeger R; Ak M; Maissen M; Kudura K; Barysch MJ; Levesque MP; Cheng PF; Dummer R; Mangana J
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208218
[TBL] [Abstract][Full Text] [Related]
34. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients.
Tong J; Kartolo A; Yeung C; Hopman W; Baetz T
Curr Oncol; 2022 Oct; 29(10):7953-7963. PubMed ID: 36290906
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
37. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
[TBL] [Abstract][Full Text] [Related]
38. Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.
Montaudié H; Beranger GE; Reinier F; Nottet N; Martin H; Picard-Gauci A; Troin L; Ballotti R; Passeron T
Pigment Cell Melanoma Res; 2021 Sep; 34(5):978-983. PubMed ID: 33449414
[TBL] [Abstract][Full Text] [Related]
39. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
